Education
About Us
Working with TipRanks
Follow Us
Dr. Hoenle AG (GB:0O27)
LSE:0O27
0O27 Stock Chart & Stats
€8.12
-€0.14(-1.99%)
At close: 4:00 PM EST
€8.12
-€0.14(-1.99%)
Day’s Range― - ―
52-Week Range€6.70 - €11.70
Previous CloseN/A
Volume1.10K
Average Volume (3M)689.00
Market Cap
€59.89M
Enterprise Value€96.15M
Total Cash (Recent Filing)€7.75M
Total Debt (Recent Filing)€48.25M
Price to Earnings (P/E)―
Beta1.05
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding6,062,930
10 Day Avg. Volume2,033
30 Day Avg. Volume689
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)0.65
Price to Sales (P/S)0.53
P/FCF Ratio15.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)€100.27M
Bulls Say, Bears Say
Bulls Say
Recurring Aftermarket RevenueDr. Hönle’s business collects recurring revenue from consumables, lamps and services tied to installed UV systems. An installed-base aftermarket supports steadier revenue and cash flow, cushions cyclical capital spending, and helps sustain margins over the medium term.
Operating Improvement In 2025A sharper EBIT narrowing and improved EBITDA margin in 2025 indicates management progress on cost control, product mix or restructuring. Durable operating leverage recovery would underpin future profitability and reduce the need for persistent external funding.
Improving Cash Flow & Lower LeverageDeclining debt since 2023 combined with positive operating and free cash flow in 2023–2025 enhances balance-sheet flexibility. Stronger FCF and lower leverage reduce refinancing risk and provide internal funding capacity for capex, R&D or working capital over the medium term.
Bears Say
Multi-year Revenue DeclineSustained top-line decline from 2022–2025 signals weakening end-market demand or competitive pressure in core UV segments. Shrinking revenue undermines scale benefits, constrains reinvestment, and raises the bar for restoring profitable growth and long-term margin expansion.
Persistent Net LossesContinued net losses and negative margins across multiple years erode equity and limit retained capital for growth. Without sustained profit conversion, the company may face pressure on returns, reduced strategic optionality, and potential need for external capital to fund operations.
Volatile Historical Cash FlowHistorical swings in operating and free cash flow complicate forecasting and increase reliance on financing in downturns. Volatility raises execution risk for sustaining aftermarket support, R&D and capex, and could force dilutive or costly funding if positive trends do not persist.
Dr. Hoenle AG News
0O27 FAQ
What was Dr. Hoenle AG’s price range in the past 12 months?
Dr. Hoenle AG lowest share price was €6.70 and its highest was €11.70 in the past 12 months.
What is Dr. Hoenle AG’s market cap?
Dr. Hoenle AG’s market cap is €59.89M.
When is Dr. Hoenle AG’s upcoming earnings report date?
Dr. Hoenle AG’s upcoming earnings report date is May 13, 2026 which is in 70 days.
How were Dr. Hoenle AG’s earnings last quarter?
Dr. Hoenle AG released its earnings results on Feb 24, 2026. The company reported -€0.25 earnings per share for the quarter, missing the consensus estimate of -€0.215 by -€0.035.
Is Dr. Hoenle AG overvalued?
According to Wall Street analysts Dr. Hoenle AG’s price is currently Overvalued.
Does Dr. Hoenle AG pay dividends?
Dr. Hoenle AG pays a Annually dividend of €0.2 which represents an annual dividend yield of N/A. See more information on Dr. Hoenle AG dividends here
What is Dr. Hoenle AG’s EPS estimate?
Dr. Hoenle AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Dr. Hoenle AG have?
Dr. Hoenle AG has 6,062,930 shares outstanding.
What happened to Dr. Hoenle AG’s price movement after its last earnings report?
Dr. Hoenle AG reported an EPS of -€0.25 in its last earnings report, missing expectations of -€0.215. Following the earnings report the stock price went up 8.421%.
Which hedge fund is a major shareholder of Dr. Hoenle AG?
Currently, no hedge funds are holding shares in GB:0O27
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Dr. Hoenle AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.78%
12-Months-Change
Fundamentals
Return on Equity
-15.84%
Trailing 12-Months
Asset Growth
-11.57%
Trailing 12-Months
Company Description
Dr. Hoenle AG
Dr. Hönle AG supplies industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for applications, such as consumer electronics, medical technology, optics and opto electronics, automotive, and glass processing. The Equipment & Systems segment engages in the drying of inks and coatings, curing of adhesives and plastics, disinfecting surfaces, and solar simulation. The Glass & Lamps segment offers quartz glass tubing and rods for the lamp, automotive, semiconductor, and fibre cable industries, as well as lamps for water disinfection, and the drying of coatings and adhesives. The company was founded in 1976 and is headquartered in Munich, Germany.
Technical Analysis
Options Prices
Currently, No data available
---